(IOVA)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Iovance Biotherapeutics, Inc., tijorat bosqichidagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlar va xalqaro miqyosda metastatik melanom va boshqa qattiq o'smali saratonlarni davolash uchun avtologik o'simta infiltratsiya qiluvchi limfotsitlardan foydalangan holda hujayra terapiyalarini ishlab chiqadi va tijoratlashtiradi. Kompaniya Amtagvi, qattiq o'smali saraton uchun individual T-hujayrali terapiyasini va ilgari davolangan, rezektsiya qilinmaydigan yoki metastatik melanomali kattalar bemorlarini davolash uchun; va Proleukin, metastatik melanomali va metastatik buyrak hujayrali karsinomali bemorlarni davolash uchun interleykin-2 mahsulotini taklif etadi. Shuningdek, u melanom, bachadon bo'yni saratoni, kichik hujayrali bo'lmagan o'pka saratoni (NSCLC), endometriyal saraton va bosh va bo'yinning yassi hujayrali karsinomasini (HNSCC) davolash uchun lifileucel; melanom va HNSCCni davolash uchun LN-145-S1; NSCLCni davolash uchun LN-145 Gen 3 va asosiy biopsiya; melanom va HNSCCni davolash uchun LN-145 Gen 3; surunkali limfotsitar leykemiya va kichik limfotsitar limfomani davolash uchun IOV-2001; melanom va NSCLCni davolash uchun IOV-4001; va TIL terapiyasi davolash rejimida foydalanish uchun IOV-3001ni ishlab chiqadi. Kompaniya Milliy Sog'liqni Saqlash Institutlari; Milliy Saraton Instituti; Cellectis S.A.; Novartis Pharma AG; va Boehringer Ingelheim Biopharmaceuticals GmbH bilan hamkorlik va litsenzion kelishuvlarga ega. Kompaniya ilgari Lion Biotechnologies, Inc. nomi bilan tanilgan va 2017 yil iyun oyida Iovance Biotherapeutics, Inc. nomiga o'zgargan. Iovance Biotherapeutics, Inc. 2007 yilda ro'yxatga olingan va Kaliforniyaning San-Karlos shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Frederick G. Vogt Esq., J.D., Ph.D. | Interim CEO, President, General Counsel, Corporate Secretary & Director |
| Dr. Friedrich Graf Finckenstein M.D. | Chief Medical Officer |
| Dr. Igor P. Bilinsky Ph.D. | Chief Operating Officer |
| Dr. Raj K. Puri M.D., Ph.D. | Chief Regulatory Officer |
| Mr. Brian Shew M.B.A. | Senior VP & Head of Digital and Information Technology |
| Mr. Howard B. Johnson M.B.A. | Chief Business Officer |
| Mr. Matthew W. Rosinack | Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-20 | 8-K | tm269367d1_8k.htm |
| 2026-01-09 | 8-K | tm262669d1_8k.htm |
| 2025-11-12 | S-8 | tm2522540d2_s8.htm |
| 2025-11-06 | 8-K | tm2530236d1_8k.htm |
| 2025-08-29 | 8-K | tm2524604d1_8k.htm |
| 2025-08-22 | 8-K | tm2524060d1_8k.htm |
| 2025-08-19 | 8-K | tm2523802d1_8k.htm |
| 2025-08-07 | 8-K | tm2522769d1_8k.htm |
| 2025-07-15 | 8-K | tm2520947d1_8k.htm |
| 2025-07-03 | 8-K | tm2519601d1_8k.htm |
| Ms. Corleen M. Roche | Chief Financial Officer |
| Ms. Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications |
| Ms. Tracy Winton | Executive Vice President of Human Resources |